AL amyloidosis is rated under diagnostic code 7717 at 100 percent. It is on the Agent Orange presumptive list, so veterans with qualifying herbicide exposure service and a confirmed diagnosis do not need a medical opinion linking it to service.
Cholangiocarcinoma (bile duct cancer) is rated at 100 percent under 38 CFR 4.114, DC 7343 during active disease and for 6 months after therapy ends. Listed as a radiation presumptive cancer under 38 CFR 3.311.
Bladder cancer is rated at 100 percent during active treatment under diagnostic code 7528. Residuals are rated under the appropriate genitourinary criteria after treatment ends.
Malignant brain tumors are rated 100 percent under diagnostic code 8002 during active disease, and the 100 percent rating continues for 2 years following the end of surgery, chemotherapy, or other treatment. After that, if the residuals have stabilized, the rating is based on the neurological residuals, with a minimum rating of 30 percent.
Breast cancer is rated at 100 percent during active treatment under diagnostic code 7630. Residuals after treatment are rated under the appropriate criteria.
Cervical cancer is rated under diagnostic code 7627 (malignant neoplasms of the gynecological system) at 100 percent while the cancer is active and for six months after treatment ends. VA then holds a mandatory examination and rates the lasting effects, such as bladder, bowel, or gynecological dysfunction from surgery or radiation, each under its own criteria.
Colorectal cancer is rated at 100 percent during active treatment under diagnostic code 7343. Residuals after treatment are rated under the appropriate digestive system criteria.
Endometrial cancer is rated under diagnostic code 7627 (malignant neoplasms of the gynecological system) at 100 percent while the cancer is active and for six months after treatment ends. After the mandatory follow up examination, VA rates the residuals, such as the effects of hysterectomy or radiation, each under its own criteria.
Esophageal cancer is rated at 100 percent under diagnostic code 7343 during active treatment, then by residuals such as dysphagia, GERD, or weight loss.
Malignant neoplasms of the eye, orbit, and adnexa (such as ocular melanoma) are rated under diagnostic code 6014 at 100 percent during active disease and treatment, continuing for six months after treatment ends, then rated on residuals such as visual impairment or disfigurement.
Gallbladder cancer is rated at 100 percent under 38 CFR 4.114, DC 7343 during active disease and for 6 months after therapy ends. Listed as a radiation presumptive cancer under 38 CFR 3.311.
Malignant neoplasms of the digestive system are rated under diagnostic code 7343 at 100 percent while active and during treatment, continued for 6 months after treatment ends, then rated on residuals. Gastrointestinal cancer of any type is on the PACT Act presumptive list for veterans with qualifying burn pit era service.
Glioblastoma is rated 100 percent under diagnostic code 8002 while the disease is active, and the 100 percent rating continues for 2 years following the end of surgery, chemotherapy, or other treatment. After that, if the residuals have stabilized, the rating is based on the neurological residuals, with a minimum rating of 30 percent.
Active head and neck cancer is rated at 100 percent while the disease is active and for six months after treatment ends, followed by a mandatory VA examination. There is no single diagnostic code for every head and neck cancer: the code follows the primary site, so respiratory tract sites such as the larynx, trachea, and nasopharynx fall under DC 6819, oral cavity and pharynx sites fall under the digestive cancer code, and thyroid cancer has a code of its own. After the 100 percent window, each residual is rated under the code for the affected function and the ratings are combined. Head and neck cancers of any type are PACT Act presumptive for qualifying toxic exposures.
Hodgkin's lymphoma is rated at 100 percent under diagnostic code 7709 during active disease, then by residuals such as immunodeficiency or organ involvement.
Laryngeal cancer is rated at 100 percent under diagnostic code 6819 during active treatment, then by residuals such as aphonia or chronic tracheostomy.
Leukemia is rated at 100 percent under diagnostic code 7703 during active disease. After remission, residuals are rated under the appropriate hematologic or systemic criteria.
Liver cancer is rated at 100 percent under diagnostic code 7343 during active treatment, then by residuals such as cirrhosis, ascites, or hepatic encephalopathy.
Active lung cancer is rated at 100 percent under diagnostic code 6819. After active treatment ends, residuals such as breathing impairment drive the rating.
Cancers of the lymphatic system are rated at 100 percent during active disease and treatment (diagnostic code 7709 for Hodgkin's lymphoma, 7715 for non Hodgkin's lymphoma), then rated on residuals. Lymphatic cancer of any type and lymphoma of any type are both named on the PACT Act presumptive list.
Breast cancer in men is rated under diagnostic code 7630 at 100 percent while active and during treatment, continued for 6 months after treatment ends, then rated on residuals. VA expressly added male breast cancer to the PACT Act presumptive list in 2024.
Mastectomy residuals are rated under diagnostic code 7626 at 0, 30, 40, 50, or 80 percent based on the type and extent of breast surgery.
Malignant melanoma is rated at 100 percent during active treatment under diagnostic code 7833, then by residuals (scarring, lymph node removal, organ involvement) after treatment ends.
Mesothelioma is rated at 100 percent under diagnostic code 6819 during active disease, then by residuals.
MGUS is rated under diagnostic code 7712: 0 percent while asymptomatic, including smoldering myeloma, and 100 percent if it progresses to symptomatic multiple myeloma. The PACT Act added MGUS to the Agent Orange presumptive list, so qualifying service plus the diagnosis establishes service connection.
Multiple myeloma is rated under diagnostic code 7712: 100 percent for symptomatic disease and 0 percent for asymptomatic, smoldering, or indolent disease. The 100 percent rating continues for five years after the diagnosis of symptomatic multiple myeloma, followed by a mandatory VA examination; any reduction must follow the procedures of 38 CFR 3.105(e) and 3.344.
Myelodysplastic syndromes are rated under diagnostic code 7725: 100 percent when a stem cell transplant or chemotherapy is required, 60 percent for 4 or more transfusions per year or 3 or more hospitalizations for infection, and 30 percent for 1 to 3 transfusions per year, 1 to 2 infection hospitalizations, or ongoing biologic therapy. MDS appears on the Camp Lejeune presumptive list and VA added it to the burn pit presumptions in 2025.
Non-Hodgkin's lymphoma is rated at 100 percent under diagnostic code 7715 during active disease, then by residuals such as immunodeficiency, anemia, or organ involvement.
Oral or pharyngeal cancer is rated at 100 percent under diagnostic code 7343 during active treatment, then by residuals such as dysphagia or speech impairment.
Ovarian cancer is rated under diagnostic code 7627 (malignant neoplasms of the gynecological system) at 100 percent while the cancer is active and continuing beyond treatment; six months after treatment ends, a mandatory VA examination sets the ongoing rating based on residuals, such as removal of both ovaries (30 percent under diagnostic code 7619) and special monthly compensation under subsection (k).
Pancreatic cancer is rated at 100 percent under diagnostic code 7343 during active treatment, then by residuals such as chronic pancreatitis, malabsorption, or diabetes.
Penile cancer is rated under diagnostic code 7528 (malignant neoplasms of the genitourinary system) at 100 percent while active and during treatment, continued for 6 months after treatment ends, then rated on residuals such as voiding dysfunction. It falls under the PACT Act presumption for reproductive cancer of any type.
Polycythemia vera is rated under diagnostic code 7704: 10 percent for phlebotomy 3 or fewer times a year or intermittent biologic therapy, 30 percent for phlebotomy 4 to 5 times a year or continuous therapy to hold counts, 60 percent for phlebotomy 6 or more times a year or molecularly targeted therapy, and 100 percent when stem cell transplant or chemotherapy is required.
Primary myelofibrosis is rated under diagnostic code 7718: 100 percent for continuous myelosuppressive therapy or for 6 months after admission for stem cell transplant, chemotherapy, or interferon; 70 percent when therapy is needed to keep platelets under 500,000; 30 percent when therapy holds platelets in the 200,000 to 400,000 range or white cells at 4,000 to 10,000; and 0 percent when asymptomatic. VA added myelofibrosis to the burn pit presumptive list in 2025.
Prostate cancer is rated under diagnostic code 7528 at 100 percent during active disease and treatment, with a mandatory review six months after treatment ends, then rated on residuals.
Renal cell carcinoma is rated at 100 percent under diagnostic code 7528 during active treatment, then by residuals such as kidney function loss and voiding dysfunction.
Malignant neoplasms of the reproductive organs are rated at 100 percent while active and during treatment (diagnostic code 7627 for gynecological and breast cancers, 7528 for male reproductive cancers), then rated on residuals. Reproductive cancer of any type is on the PACT Act presumptive list, and VA expanded the family in 2024 to expressly include male breast cancer, urethral cancer, and cancer of the paraurethral glands.
Malignant neoplasms of the respiratory system are rated under diagnostic code 6819 at 100 percent while the cancer is active and through treatment, then rated on residuals under the respiratory criteria in 38 CFR 4.97. Presumptive coverage depends on the exposure: the Agent Orange list covers cancers of the lung, bronchus, larynx, and trachea, while the PACT Act covers respiratory cancer of any type for qualifying burn pit and airborne hazard exposure.
Small intestine cancer is rated at 100 percent under 38 CFR 4.114, DC 7343 during active disease and for 6 months after therapy ends. Listed as a radiation presumptive cancer under 38 CFR 3.311 and as a GI cancer presumptive under the PACT Act.
Soft tissue sarcoma (of muscle, fat, or fibrous connective tissue) is rated under diagnostic code 5329 at 100 percent while active and during treatment, continued for 6 months after treatment ends, then rated on residual impairment of function. Soft tissue sarcomas are on the Agent Orange presumptive list.
Solitary plasmacytoma is rated under diagnostic code 7724 at 100 percent during active disease or treatment, continuing for six months after treatment ends, then rated on residuals. If it progresses to multiple myeloma, it is rated as symptomatic multiple myeloma at 100 percent.
Stomach cancer is rated at 100 percent under diagnostic code 7343 during active treatment, then by digestive residuals such as dumping syndrome, malabsorption, or anemia.
Testicular cancer is rated under diagnostic code 7528 (malignant neoplasms of the genitourinary system) at 100 percent while the cancer is active and for six months after treatment ends. After the mandatory follow up examination, VA rates the residuals: removal of both testes rates 30 percent under diagnostic code 7524, removal of one rates 0 percent, and special monthly compensation under subsection (k) applies for the anatomical loss of a creative organ.
Thymoma is rated under 38 CFR 4.97 DC 6819 (malignant intrathoracic neoplasm) at 100 percent during active disease and through 6 months after treatment, then by residuals.
Thyroid cancer is rated at 100 percent under diagnostic code 7914 (malignant neoplasm of the endocrine system) while the cancer is active and for six months after treatment ends. After a mandatory follow up examination, VA rates the residuals, most often hypothyroidism under diagnostic code 7903 when the thyroid was removed.
Cancer of the urethra or paraurethral glands is rated under diagnostic code 7528 at 100 percent while active and during treatment, continued for 6 months after treatment ends, then rated on residuals, most often as voiding dysfunction. VA expressly added urethral cancer and cancer of the paraurethral glands to the PACT Act presumptive list in 2024.
Cancers of the kidney, ureter, and urethra rate 100 percent under 38 CFR 4.115b, DC 7528 during active disease and for 6 months after therapy ends. Listed as a radiation presumptive cancer under 38 CFR 3.311 (urinary-tract cancers) and as a PACT Act presumptive cancer (kidney cancer).
Malignant neoplasms of the vulva or vagina are rated under diagnostic code 7627 at 100 percent while active and during treatment, continued for 6 months after treatment ends, then rated on residuals. These cancers fall under the PACT Act presumption for reproductive cancer of any type.